A 60-year-old woman presented with asymmetric distal limb weakness and muscle atrophy. Electrophysiologic study revealed demyelinating polyneuropathy, and she was diagnosed with multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy as a subtype of chronic inflammatory demyelinating polyneuropathy (CIDP) based on the established diagnostic criteria.^[@R1]^ Anti-neurofascin155 antibody was negative. Cervical and lumbosacral nerve roots showed asymmetric multifocal hypertrophy ([figure 1](#F1){ref-type="fig"}), which were distinct from those in typical CIDP.^[@R2]^ Brain MRI revealed multifocal nodular hypertrophy of trigeminal nerves ([figure 2](#F2){ref-type="fig"} and [video 1](#SM1){ref-type="supplementary-material"}). These hypertrophic patterns in trigeminal nerves as well as nerve roots might be characteristics of MADSAM neuropathy.

![Cervical and lumbosacral nerve roots hypertrophy\
(A and B) Coronal cervical STIR MRI; (C--E), coronal lumbar STIR MRI. STIR = short tau inversion recovery.](NEURIMMINFL2019019745f1){#F1}

![Trigeminal nerves hypertrophy\
(A) Sagittal T2-weighted MRI; (B and C) coronal fluid-attenuated inversion recovery MRI; (D--F) axial T2-weighted MRI.](NEURIMMINFL2019019745f2){#F2}
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3D reconstruction image of trigeminal nerves hypertrophy was made based on thin-slice images of brain FLAIR MRI using Synapse Vincent (Fuji film, Co, Ltd, Tokyo, Japan). Asymmetric multifocal nodular hypertrophy of trigeminal nerves can be visually recognized.Download Supplementary Video 1 via [http://dx.doi.org/10.1212/000553_Video_1](10.1212/000553_Video_1)
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